# US 2024/0002954 A1 · Evaluation method for bisulfite reagent and genetic test method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002954 A1
- Document ID: US20240002954A1
- Status: Published application
- Kind: A1
- Application number: 18/357,453
- Filed: 2023-07-24
- Published: 2024-01-04
- Earliest claimed: 2021-02-25
- Assignees: FUJIFILM Corporation
- Applicants: FUJIFILM Corporation
- Inventors: Maiko WAKITA
- Web page: https://patentgrep.com/patent/US20240002954A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 14/435: from animals; from humans
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12Q 1/68: involving nucleic acids
- C12Q 1/6869: Methods for sequencing
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

There are provided an evaluation method for selecting a bisulfite reagent according to a target of a genetic test and a genetic test method including selecting a bisulfite reagent according to a target of a genetic test. In the evaluation method for a bisulfite reagent, a rate 1 of an error in which an unmethylated CpG site is determined to be in a methylated state is compared with a rate 2 of an error in which a methylated CpG site is determined to be in an unmethylated state. In the genetic test method, the bisulfite reagent is selected according to a history of illness of a subject and a correlation between a disease and methylation or unmethylation of a gene.

## Claims

### Claim 1

A method of evaluating a bisulfite reagent, the method comprising the following (a) to (c):
(a) preparing a DNA sample 1 in which a CpG site to be measured is not methylated, treating the DNA sample 1 with a bisulfite reagent to be evaluated, and subsequently measuring a degree of methylation of the CpG site to be measured to calculate an error rate 1, where the error rate 1 is an average value of the degree of methylation of the CpG site to be measured;
(b) preparing a DNA sample 2 which has the same sequence as the DNA sample 1 and in which the CpG site to be measured is methylated, treating the DNA sample 2 with the bisulfite reagent to be evaluated, and subsequently measuring a degree of methylation of the CpG site to be measured to calculate an error rate 2, where the error rate 2 is calculated by 100—(an average value of the degree of methylation of the CpG site to be measured) and
(c) comparing the error rate 1 with the error rate 2, wherein when a relationship of the error rate 1≤the error rate 2 is satisfied, the bisulfite reagent is evaluated as having an inappropriate conversion tendency, and wherein when a relationship of the error rate 1>the error rate 2 is satisfied, the bisulfite reagent is evaluated as having a failed conversion tendency.

### Claim 2 (depends on 1)

A method of a genetic test which analyzes a degree of methylation of a gene of a subject who has no history of illness in regard to a target disease onset or progression of which correlates with methylation or unmethylation of the gene, the method comprising treating DNA of the subject with a bisulfite reagent,
wherein when a disease onset or progression of which correlates with methylation of the gene is the target disease, the bisulfite reagent is a bisulfite reagent which has been evaluated by the method according to claim 1 as having an inappropriate conversion tendency, and
wherein when a disease onset or progression of which correlates with unmethylation of the gene is the target disease, the bisulfite reagent is a bisulfite reagent which has been evaluated by the method according to claim 1 as having a failed conversion tendency.

### Claim 3 (depends on 2)

The method according to claim 2, wherein a false positive rate and a false negative rate in the test are estimated from values of the error rate 1 and the error rate 2 in the evaluation of the bisulfite reagent.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the disease is cancer.

### Claim 5 (depends on 1)

A method of a genetic test which analyzes a degree of methylation of a gene of a subject who has a history of illness in regard to a target disease onset or progression of which correlates with methylation or unmethylation of the gene, the method comprising treating DNA of the subject with a bisulfite reagent,
wherein when a disease onset or progression of which correlates with methylation of the gene is the target disease, the bisulfite reagent is a bisulfite reagent which has been evaluated by the method according to claim 1 as having a failed conversion tendency, and
wherein when a disease onset or progression of which correlates with unmethylation of the gene is the target disease, the bisulfite reagent is a bisulfite reagent which has been evaluated by the method according to claim 1 as having an inappropriate conversion tendency.

### Claim 6 (depends on 5)

The method according to claim 5, wherein a false positive rate and a false negative rate in the test are estimated from values of the error rate 1 and the error rate 2 in the evaluation of the bisulfite reagent.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the disease is cancer.
